Sistema complementare e artrite reumatoide

Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α

Translated title of the contribution: Complement system and Rheumatoid Arthritis: Relationships with autoantibodies, serological, clinical features and anti-TNF α treatment

G. Di Muzio, E. Ballanti, M. S. Chimenti, P. Conigliaro, D. Graceffa, M. D. Guarino, E. Greco, B. Kroegler, L. Novelli, C. Perricone, R. Perricone

Research output: Contribution to journalArticle

Abstract

Objectives. Rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and complement system are involved in rheumatoid arthritis (RA) pathogenesis. Aim of this study is to investigate whether ACPA can activate the Complement system in vivo in patients with Rheumatoid Arthritis who are treated by means of traditional and/or biologic DMARDs. Methods. One-hundred fourteen RA patients (89 F/25 M) diagnosed according to 1987 ACR criteria and 30 healthy controls were enrolled. Serological analysis included ESR, CRP, complement C3, C4 and CH50, RF and ACPA. Seventy-six patients started anti-TNF α treatments and were studied also after 22 weeks. Disease activity was measured with DAS28 and response to therapy with EULAR criteria. Results. At baseline, C3, C4 and CH50 levels in RA patients were significantly higher than in controls. No demographic or clinical differences were observed between ACPA+ (n = 76) and ACPA- (n = 38) patients, nor in C3, C4 and CH50 levels. In patients undergoing anti-TNF α therapy, C3, C4 and RF were significantly reduced after 22 weeks. RF changes showed positive correlation with CH50 after 22 weeks. DAS28 significantly ameliorated after 22 weeks. Conclusions. C3, C4, CH50 levels that we studied in serum of RA patients seem to correlate with RF levels rather than ACPA, independently from the therapy administered.

Original languageItalian
Pages (from-to)73-80
Number of pages8
JournalItalian Journal of Allergy and Clinical Immunology
Volume21
Issue number3
Publication statusPublished - Sep 2011

Fingerprint

Autoantibodies
Rheumatoid Arthritis
Rheumatoid Factor
Antibodies
Proteins
Therapeutics
Complement C4
Complement C3
Antirheumatic Agents
Complement System Proteins
Demography
Serum

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Sistema complementare e artrite reumatoide : Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α. / Di Muzio, G.; Ballanti, E.; Chimenti, M. S.; Conigliaro, P.; Graceffa, D.; Guarino, M. D.; Greco, E.; Kroegler, B.; Novelli, L.; Perricone, C.; Perricone, R.

In: Italian Journal of Allergy and Clinical Immunology, Vol. 21, No. 3, 09.2011, p. 73-80.

Research output: Contribution to journalArticle

Di Muzio, G, Ballanti, E, Chimenti, MS, Conigliaro, P, Graceffa, D, Guarino, MD, Greco, E, Kroegler, B, Novelli, L, Perricone, C & Perricone, R 2011, 'Sistema complementare e artrite reumatoide: Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α', Italian Journal of Allergy and Clinical Immunology, vol. 21, no. 3, pp. 73-80.
Di Muzio, G. ; Ballanti, E. ; Chimenti, M. S. ; Conigliaro, P. ; Graceffa, D. ; Guarino, M. D. ; Greco, E. ; Kroegler, B. ; Novelli, L. ; Perricone, C. ; Perricone, R. / Sistema complementare e artrite reumatoide : Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α. In: Italian Journal of Allergy and Clinical Immunology. 2011 ; Vol. 21, No. 3. pp. 73-80.
@article{92a4c972770f451c9f27c1885e0720c9,
title = "Sistema complementare e artrite reumatoide: Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α",
abstract = "Objectives. Rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and complement system are involved in rheumatoid arthritis (RA) pathogenesis. Aim of this study is to investigate whether ACPA can activate the Complement system in vivo in patients with Rheumatoid Arthritis who are treated by means of traditional and/or biologic DMARDs. Methods. One-hundred fourteen RA patients (89 F/25 M) diagnosed according to 1987 ACR criteria and 30 healthy controls were enrolled. Serological analysis included ESR, CRP, complement C3, C4 and CH50, RF and ACPA. Seventy-six patients started anti-TNF α treatments and were studied also after 22 weeks. Disease activity was measured with DAS28 and response to therapy with EULAR criteria. Results. At baseline, C3, C4 and CH50 levels in RA patients were significantly higher than in controls. No demographic or clinical differences were observed between ACPA+ (n = 76) and ACPA- (n = 38) patients, nor in C3, C4 and CH50 levels. In patients undergoing anti-TNF α therapy, C3, C4 and RF were significantly reduced after 22 weeks. RF changes showed positive correlation with CH50 after 22 weeks. DAS28 significantly ameliorated after 22 weeks. Conclusions. C3, C4, CH50 levels that we studied in serum of RA patients seem to correlate with RF levels rather than ACPA, independently from the therapy administered.",
keywords = "Anti cyclic citrullinated peptide Abs, Anti-TNF, Complement system, Drugs, Rheumatoid arthritis, Rheumatoid factor",
author = "{Di Muzio}, G. and E. Ballanti and Chimenti, {M. S.} and P. Conigliaro and D. Graceffa and Guarino, {M. D.} and E. Greco and B. Kroegler and L. Novelli and C. Perricone and R. Perricone",
year = "2011",
month = "9",
language = "Italian",
volume = "21",
pages = "73--80",
journal = "Italian Journal of Allergy and Clinical Immunology",
issn = "1120-6373",
publisher = "Italian Society of Allergy and Clinical Immunology",
number = "3",

}

TY - JOUR

T1 - Sistema complementare e artrite reumatoide

T2 - Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α

AU - Di Muzio, G.

AU - Ballanti, E.

AU - Chimenti, M. S.

AU - Conigliaro, P.

AU - Graceffa, D.

AU - Guarino, M. D.

AU - Greco, E.

AU - Kroegler, B.

AU - Novelli, L.

AU - Perricone, C.

AU - Perricone, R.

PY - 2011/9

Y1 - 2011/9

N2 - Objectives. Rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and complement system are involved in rheumatoid arthritis (RA) pathogenesis. Aim of this study is to investigate whether ACPA can activate the Complement system in vivo in patients with Rheumatoid Arthritis who are treated by means of traditional and/or biologic DMARDs. Methods. One-hundred fourteen RA patients (89 F/25 M) diagnosed according to 1987 ACR criteria and 30 healthy controls were enrolled. Serological analysis included ESR, CRP, complement C3, C4 and CH50, RF and ACPA. Seventy-six patients started anti-TNF α treatments and were studied also after 22 weeks. Disease activity was measured with DAS28 and response to therapy with EULAR criteria. Results. At baseline, C3, C4 and CH50 levels in RA patients were significantly higher than in controls. No demographic or clinical differences were observed between ACPA+ (n = 76) and ACPA- (n = 38) patients, nor in C3, C4 and CH50 levels. In patients undergoing anti-TNF α therapy, C3, C4 and RF were significantly reduced after 22 weeks. RF changes showed positive correlation with CH50 after 22 weeks. DAS28 significantly ameliorated after 22 weeks. Conclusions. C3, C4, CH50 levels that we studied in serum of RA patients seem to correlate with RF levels rather than ACPA, independently from the therapy administered.

AB - Objectives. Rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and complement system are involved in rheumatoid arthritis (RA) pathogenesis. Aim of this study is to investigate whether ACPA can activate the Complement system in vivo in patients with Rheumatoid Arthritis who are treated by means of traditional and/or biologic DMARDs. Methods. One-hundred fourteen RA patients (89 F/25 M) diagnosed according to 1987 ACR criteria and 30 healthy controls were enrolled. Serological analysis included ESR, CRP, complement C3, C4 and CH50, RF and ACPA. Seventy-six patients started anti-TNF α treatments and were studied also after 22 weeks. Disease activity was measured with DAS28 and response to therapy with EULAR criteria. Results. At baseline, C3, C4 and CH50 levels in RA patients were significantly higher than in controls. No demographic or clinical differences were observed between ACPA+ (n = 76) and ACPA- (n = 38) patients, nor in C3, C4 and CH50 levels. In patients undergoing anti-TNF α therapy, C3, C4 and RF were significantly reduced after 22 weeks. RF changes showed positive correlation with CH50 after 22 weeks. DAS28 significantly ameliorated after 22 weeks. Conclusions. C3, C4, CH50 levels that we studied in serum of RA patients seem to correlate with RF levels rather than ACPA, independently from the therapy administered.

KW - Anti cyclic citrullinated peptide Abs

KW - Anti-TNF

KW - Complement system

KW - Drugs

KW - Rheumatoid arthritis

KW - Rheumatoid factor

UR - http://www.scopus.com/inward/record.url?scp=84857595197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857595197&partnerID=8YFLogxK

M3 - Articolo

VL - 21

SP - 73

EP - 80

JO - Italian Journal of Allergy and Clinical Immunology

JF - Italian Journal of Allergy and Clinical Immunology

SN - 1120-6373

IS - 3

ER -